Clinical Trials
25 trialsA Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Nimbus Therapeutics
Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer
Blokhin's Russian Cancer Research Center
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ARETHUSA
IFOM ETS - The AIRC Institute of Molecular Oncology
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
KEYNOTE 158
Merck Sharp & Dohme LLC
NIPICOL
GERCOR - Multidisciplinary Oncology Cooperative Group
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
START-001
Marengo Therapeutics, Inc.
PREMICES
GERCOR - Multidisciplinary Oncology Cooperative Group
INFINITY
Gruppo Oncologico del Nord-Ovest
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
M.D. Anderson Cancer Center
AuspiCiOus
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
AcSé
UNICANCER
NIECE
Assistance Publique - Hôpitaux de Paris
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
POLEM
Royal Marsden NHS Foundation Trust
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Apollomics (Australia) Pty. Ltd.
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Washington
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
Gustave Roussy, Cancer Campus, Grand Paris
Implementation of a New Strategy to Identify HNPCC Patients
Radboud University Medical Center